Thiogenesis Therapeutics Corp (TTIPF)

$0.00 -2.58 (-99.94%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 500
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 0%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada.

Industry: Biotechnology
Sector: Healthcare
Phone: 888-223-9165
Address:
4 King Street West, Suite 401, Toronto, Canada
wavess
wavess Jul. 30 at 4:17 PM
$TTIPF Yesterday, Thiogenesis Therapeutics (TTI.v TTIPF) announced the upsizing of its previously announced non-brokered private placement for approximately $4M due to strong investor demand, with the proceeds expected to fund clinical trial expenses for TTI's lead asset, TTI‑0102, specifically its MELAS Phase 2 study, as well as manufacturing additional TTI‑0102 for future trials and general working capital: https://www.msn.com/en-us/money/markets/thiogenesis-upsizes-private-placement-to-5-3m-common-shares/ar-AA1JvEMy In advancing a high-potential rare disease pipeline centered on TTI‑0102, a next-generation cysteamine prodrug targeting mitochondrial dysfunction, TTI has three active clinical trials underway, including a European Phase 2 trial for MELAS, a U.S.-based study for Leigh Syndrome, and a third program for MASH. Full Pipeline Breakdown: https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/
0 · Reply
wavess
wavess Jul. 25 at 8:07 PM
$TTIPF According to recent market research, the global market for Leigh syndrome treatments was estimated at approximately US $273 million in 2025 and is projected to grow to around US $436 million by 2032, at a compound annual growth rate of about 6.9% (Source: https://www.coherentmarketinsights.com/industry-reports/global-leigh-syndrome-treatment-market) With no approved therapies and limited options beyond symptom management, Thiogenesis Therapeutics is positioning itself as a first mover having initiated patient dosing in its European Phase 2 trial for TTI‑0102 for Leigh Syndrome: https://x.com/StckMasterFlash/status/1932861013423984766 Posted on Behalf of Thiogenesis Therapeutics Corp.
0 · Reply
wavess
wavess Jul. 24 at 10:09 PM
$TTIPF Thiogenesis Therapeutics is strategically advancing its lead compound, TTI‑0102, through a robust pipeline of rare pediatric indications facing zero approved treatments. Currently dosing MELAS patients in a Phase 2 trial for the orphan mitochondrial disorder, part of a MELAS market projected to reach nearly USD 494 million by 2035, TTI is additionally initiating a Phase 2a trial in Leigh Syndrome Spectrum in collaboration with CHOP (Children’s Hospital of Philadelphia), targeting a disease impacting roughly 1 in 40,000 newborns. In parallel, the EMA’s CHMP has endorsed TTI's Phase 2a IMPD for pediatric MASH in children aged 10–17—an indication grounded in escalating pediatric fatty liver disease and supported by recent EU patent protection through 2038. Check out the full pipeline here: https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/ Posted on Behalf of Thiogenesis Therapeutics Corp.
0 · Reply
wavess
wavess Jul. 23 at 9:00 PM
$TTIPF As the MELAS syndrome market is projected to grow to nearly half a billion dollars by 2035 (source: https://www.biospace.com/press-releases/melas-syndrome-market-size-to-reach-usd-494-2-million-by-2035-impelled-by-increasing-prevalence-of-genetic-mutations), Thiogenesis Therapeutics has begun dosing patients in its European Phase 2 trial for TTI‑0102, a next-generation cysteamine prodrug designed to target the underlying antioxidant deficiencies in MELAS. With no approved treatments currently available and an interim efficacy readout expected this fall, check out how this trial could mark a critical step toward addressing a major unmet need in mitochondrial medicine: https://x.com/StckMasterFlash/status/1922740812284055630
0 · Reply
stockhawk12
stockhawk12 Jul. 22 at 10:59 PM
$TTIPF Clinical-stage biotech company Thiogenesis Therapeutics (TTI.v TTIPF) is developing next-gen therapies for mitochondrial diseases. Recent milestones include EU patent protection through 2038, bolstering its IP position ahead of key trials. *Posted on behalf of Thiogenesis Therapeutics Corp. https://x.com/StckMasterFlash/status/1944873428017611032
0 · Reply
wavess
wavess Jul. 21 at 7:51 PM
$TTIPF Poised at the intersection of rare disease innovation and clinical momentum, Thiogenesis Therapeutics (TTI.v TTIPF) is advancing three active Phase 2 trials while raising capital through an ongoing private placement, positioning itself for a pivotal second half of 2025 as key data readouts approach: https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/
0 · Reply
wavess
wavess Jul. 18 at 3:57 PM
$TTIPF Continuing to make progress on its clinical pipeline, Thiogenesis Therapeutics has three Phase 2 trials now advancing for its lead compound, TTI-0102, a next-generation, controlled-release prodrug of cysteamine developed to reduce GI toxicity and improve dosing compliance: https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/ 1) MELAS (Europe): Phase 2 trial currently enrolling with interim efficacy data expected in Q3 2025. 2) Leigh Syndrome Spectrum (U.S.): Phase 2a trial launching in collaboration with the Children’s Hospital of Philadelphia (CHOP) after receiving IND clearance. 3) Pediatric MASH (U.S.): A Phase 2a trial for this growing metabolic liver disease is set to begin following an IMPD filing later this year.
0 · Reply
wavess
wavess Jul. 17 at 5:49 PM
$TTIPF Today, Thiogenesis Therapeutics announced a non-brokered private placement for gross proceeds of $1.5 million to support clinical trial expenses for the company’s MELAS program, production of additional TTI-0102 for future trials: https://www.newsfilecorp.com/release/259055/Thiogenesis-Announces-NonBrokered-Private-Placement-of-Common-Shares Currently, TTI has three Phase 2 trials ongoing for its lead asset, TTI-0102, a next-generation, controlled-release prodrug of cysteamine designed to overcome the GI toxicity and dosing issues seen with earlier compounds. These trials target high-need pediatric and orphan indications rooted in mitochondrial dysfunction and oxidative stress, including MELAS (interim data expected in Q3 2025), Leigh Syndrome Spectrum (launching in partnership with the Children’s Hospital of Philadelphia), and pediatric MASH. Full Clinical Roadmap: https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/
0 · Reply
wavess
wavess Jul. 16 at 4:38 PM
$TTIPF Targeting the root of mitochondrial dysfunction with a next-gen cysteamine prodrug, Thiogenesis Therapeutics is advancing three Phase 2 programs for rare, high-need pediatric diseases—each with no approved treatment and billion-dollar market potential. With interim data for MELAS due Q3 2025 and trials launching for Leigh Syndrome and pediatric MASH, TTI is poised for a catalyst-rich year backed by proven leadership and a scalable redox-based platform. Check out the full story here: https://x.com/StckMasterFlash/status/1944873428017611032
0 · Reply
wavess
wavess Jul. 15 at 4:50 PM
$TTIPF New company breakdown for Thiogenesis Therapeutics: https://x.com/StckMasterFlash/status/1944873428017611032 Advancing a next-generation cysteamine platform with broad potential across mitochondrial and oxidative stress-driven disorders, TTI has three active Phase 2 programs, including MELAS, Leigh Syndrome, and pediatric MASH, positioning the company for multiple near-term catalysts in high-need, billion-dollar orphan markets.
0 · Reply
Latest News on TTIPF
No data available.
wavess
wavess Jul. 30 at 4:17 PM
$TTIPF Yesterday, Thiogenesis Therapeutics (TTI.v TTIPF) announced the upsizing of its previously announced non-brokered private placement for approximately $4M due to strong investor demand, with the proceeds expected to fund clinical trial expenses for TTI's lead asset, TTI‑0102, specifically its MELAS Phase 2 study, as well as manufacturing additional TTI‑0102 for future trials and general working capital: https://www.msn.com/en-us/money/markets/thiogenesis-upsizes-private-placement-to-5-3m-common-shares/ar-AA1JvEMy In advancing a high-potential rare disease pipeline centered on TTI‑0102, a next-generation cysteamine prodrug targeting mitochondrial dysfunction, TTI has three active clinical trials underway, including a European Phase 2 trial for MELAS, a U.S.-based study for Leigh Syndrome, and a third program for MASH. Full Pipeline Breakdown: https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/
0 · Reply
wavess
wavess Jul. 25 at 8:07 PM
$TTIPF According to recent market research, the global market for Leigh syndrome treatments was estimated at approximately US $273 million in 2025 and is projected to grow to around US $436 million by 2032, at a compound annual growth rate of about 6.9% (Source: https://www.coherentmarketinsights.com/industry-reports/global-leigh-syndrome-treatment-market) With no approved therapies and limited options beyond symptom management, Thiogenesis Therapeutics is positioning itself as a first mover having initiated patient dosing in its European Phase 2 trial for TTI‑0102 for Leigh Syndrome: https://x.com/StckMasterFlash/status/1932861013423984766 Posted on Behalf of Thiogenesis Therapeutics Corp.
0 · Reply
wavess
wavess Jul. 24 at 10:09 PM
$TTIPF Thiogenesis Therapeutics is strategically advancing its lead compound, TTI‑0102, through a robust pipeline of rare pediatric indications facing zero approved treatments. Currently dosing MELAS patients in a Phase 2 trial for the orphan mitochondrial disorder, part of a MELAS market projected to reach nearly USD 494 million by 2035, TTI is additionally initiating a Phase 2a trial in Leigh Syndrome Spectrum in collaboration with CHOP (Children’s Hospital of Philadelphia), targeting a disease impacting roughly 1 in 40,000 newborns. In parallel, the EMA’s CHMP has endorsed TTI's Phase 2a IMPD for pediatric MASH in children aged 10–17—an indication grounded in escalating pediatric fatty liver disease and supported by recent EU patent protection through 2038. Check out the full pipeline here: https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/ Posted on Behalf of Thiogenesis Therapeutics Corp.
0 · Reply
wavess
wavess Jul. 23 at 9:00 PM
$TTIPF As the MELAS syndrome market is projected to grow to nearly half a billion dollars by 2035 (source: https://www.biospace.com/press-releases/melas-syndrome-market-size-to-reach-usd-494-2-million-by-2035-impelled-by-increasing-prevalence-of-genetic-mutations), Thiogenesis Therapeutics has begun dosing patients in its European Phase 2 trial for TTI‑0102, a next-generation cysteamine prodrug designed to target the underlying antioxidant deficiencies in MELAS. With no approved treatments currently available and an interim efficacy readout expected this fall, check out how this trial could mark a critical step toward addressing a major unmet need in mitochondrial medicine: https://x.com/StckMasterFlash/status/1922740812284055630
0 · Reply
stockhawk12
stockhawk12 Jul. 22 at 10:59 PM
$TTIPF Clinical-stage biotech company Thiogenesis Therapeutics (TTI.v TTIPF) is developing next-gen therapies for mitochondrial diseases. Recent milestones include EU patent protection through 2038, bolstering its IP position ahead of key trials. *Posted on behalf of Thiogenesis Therapeutics Corp. https://x.com/StckMasterFlash/status/1944873428017611032
0 · Reply
wavess
wavess Jul. 21 at 7:51 PM
$TTIPF Poised at the intersection of rare disease innovation and clinical momentum, Thiogenesis Therapeutics (TTI.v TTIPF) is advancing three active Phase 2 trials while raising capital through an ongoing private placement, positioning itself for a pivotal second half of 2025 as key data readouts approach: https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/
0 · Reply
wavess
wavess Jul. 18 at 3:57 PM
$TTIPF Continuing to make progress on its clinical pipeline, Thiogenesis Therapeutics has three Phase 2 trials now advancing for its lead compound, TTI-0102, a next-generation, controlled-release prodrug of cysteamine developed to reduce GI toxicity and improve dosing compliance: https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/ 1) MELAS (Europe): Phase 2 trial currently enrolling with interim efficacy data expected in Q3 2025. 2) Leigh Syndrome Spectrum (U.S.): Phase 2a trial launching in collaboration with the Children’s Hospital of Philadelphia (CHOP) after receiving IND clearance. 3) Pediatric MASH (U.S.): A Phase 2a trial for this growing metabolic liver disease is set to begin following an IMPD filing later this year.
0 · Reply
wavess
wavess Jul. 17 at 5:49 PM
$TTIPF Today, Thiogenesis Therapeutics announced a non-brokered private placement for gross proceeds of $1.5 million to support clinical trial expenses for the company’s MELAS program, production of additional TTI-0102 for future trials: https://www.newsfilecorp.com/release/259055/Thiogenesis-Announces-NonBrokered-Private-Placement-of-Common-Shares Currently, TTI has three Phase 2 trials ongoing for its lead asset, TTI-0102, a next-generation, controlled-release prodrug of cysteamine designed to overcome the GI toxicity and dosing issues seen with earlier compounds. These trials target high-need pediatric and orphan indications rooted in mitochondrial dysfunction and oxidative stress, including MELAS (interim data expected in Q3 2025), Leigh Syndrome Spectrum (launching in partnership with the Children’s Hospital of Philadelphia), and pediatric MASH. Full Clinical Roadmap: https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/
0 · Reply
wavess
wavess Jul. 16 at 4:38 PM
$TTIPF Targeting the root of mitochondrial dysfunction with a next-gen cysteamine prodrug, Thiogenesis Therapeutics is advancing three Phase 2 programs for rare, high-need pediatric diseases—each with no approved treatment and billion-dollar market potential. With interim data for MELAS due Q3 2025 and trials launching for Leigh Syndrome and pediatric MASH, TTI is poised for a catalyst-rich year backed by proven leadership and a scalable redox-based platform. Check out the full story here: https://x.com/StckMasterFlash/status/1944873428017611032
0 · Reply
wavess
wavess Jul. 15 at 4:50 PM
$TTIPF New company breakdown for Thiogenesis Therapeutics: https://x.com/StckMasterFlash/status/1944873428017611032 Advancing a next-generation cysteamine platform with broad potential across mitochondrial and oxidative stress-driven disorders, TTI has three active Phase 2 programs, including MELAS, Leigh Syndrome, and pediatric MASH, positioning the company for multiple near-term catalysts in high-need, billion-dollar orphan markets.
0 · Reply
wavess
wavess Jul. 14 at 9:03 PM
$TTIPF Advancing best-in-class mitochondrial therapeutics with near-term human efficacy readouts, Thiogenesis Therapeutics is clinical-stage biotech company focused on developing cysteamine-based therapeutics targeting pediatric and orphan diseases rooted in mitochondrial dysfunction and oxidative stress: https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/ TTI's lead asset being developed for three Phase 2 indications, each with multi-billion dollar addressable markets and no approved therapies, including MELAS, Leigh Syndrome Spectrum (LSS) and Pediatric MASH. Corporate Presentation: https://cdn.prod.website-files.com/6324f3c1cd40a857e0ea27a4/685eda4d93c31efab5e329eb_TTI%20Corp%20-%20Presentation%20%20070125%20.pdf
0 · Reply
wavess
wavess Jul. 11 at 7:57 PM
$TTIPF Running in parallel with Phase 2 trials for MELAS and MASH, Thiogenesis Therapeutics (TTI.v TTIPF) is additionally advancing a Phase 2a trial for Leigh Syndrome—a devastating pediatric mitochondrial disorder with no approved treatments. This trial represents a major step toward validating TTI’s core platform in high-value, orphan drug markets. With dosing now underway and interim data from MELAS trials expected soon, TTI is approaching a critical inflection point that could redefine its clinical and commercial trajectory. Dive into the full clinical roadmap here: https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/ Posted on Behalf of Thiogenesis Therapeutics Corp.
0 · Reply
wavess
wavess Jul. 10 at 7:49 PM
$TTIPF Running alongside two other trials, Thiogenesis Therapeutics is advancing its European Phase 2 trial for MELAS—a rare, currently untreatable mitochondrial disease. With dosing underway in the Netherlands and France, and a 3-month interim efficacy readout expected in the near term, TTI is positioning itself for a major value inflection point in a high-need, orphan drug market. For more info on TTI and its two other current trials, refer to this breakdown: https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/
0 · Reply
wavess
wavess Jul. 7 at 7:24 PM
$TTIPF Triple Trial Momentum: Thiogenesis Therapeutics (TTI.v TTIPF) Surges on Breakthroughs in Mitochondrial & Metabolic Disease Pipeline Targeting rare, high-need diseases like MELAS, Leigh Syndrome (in partnership with CHOP), and MASH, Thiogenesis Therapeutics (TTI.v TTIPF) is gaining serious traction as its lead candidate, TTI-0102, advances through three Phase 2 trials. Backed by EMA guidance and growing regulatory momentum, TTI is emerging as a key player in pediatric and metabolic drug development. Check out the full story here: https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/
0 · Reply
wavess
wavess Jul. 4 at 9:50 PM
$TTIPF Today, Thiogenesis Therapeutics is up over 12% over 6x the average volume amid three active clinical trials for its lead candidate, TTI-0102, a prodrug designed to target mitochondrial and oxidative stress-related disorders. Check out a breakdown of TTI's current clinical pipeline here: https://x.com/StckMasterFlash/status/1937578501932192183
0 · Reply
wavess
wavess Jul. 3 at 10:07 PM
$TTIPF As the FDA faces mounting delays, Thiogenesis Therapeutics is quietly making clinical strides in Europe—recently dosing its first patient in France and expanding its Phase 2 trial for MELAS, a rare and debilitating mitochondrial disease with no approved treatments: https://x.com/StckMasterFlash/status/1935049659816214802 With interim results expected this fall, and a novel sulfur-based therapy targeting the root causes of mitochondrial dysfunction, TTI is emerging as a biotech to watch in the high-need orphan disease space, with two other active trials currently running.
0 · Reply
wavess
wavess Jul. 2 at 5:10 PM
$TTIPF Recently, Thiogenesis Therapeutics received FDA clearance to initiate a Phase 2a clinical trial for its lead candidate, TTI-0102, in patients with Leigh Syndrome Spectrum (LSS)—a rare, life-threatening mitochondrial disease with no approved therapies. Notably, the trial will be led by the Children’s Hospital of Philadelphia (CHOP), a world leader in pediatric mitochondrial research, underscoring the scientific credibility and clinical importance of this program. The two-stage trial will assess safety, pharmacokinetics, and early efficacy of TTI-0102 in both adolescent and pediatric LSS patients, with the CHOP team—led by Drs. Zarazuela Zolkipli-Cunningham and Marni Falk—highlighting its potential to deliver meaningful clinical benefit. Full News Breakdown: https://x.com/StckMasterFlash/status/1932861013423984766 Posted on Behalf of Thiogenesis Therapeutics Corp.
0 · Reply
wavess
wavess Jun. 30 at 8:16 PM
$TTIPF Advancing a rare disease pipeline, Thiogenesis Therapeutics has three active clinical trials targeting mitochondrial and oxidative stress-related disorders: 1) Phase 2a Trial in Leigh Syndrome Spectrum (LSS) – Now enrolling in collaboration with the Children’s Hospital of Philadelphia (CHOP), a global leader in pediatric mitochondrial care. 2) Phase 2 Trial in For MELAS – Running in Europe targeting a devastating mitochondrial disease with no approved treatments in the U.S. or EU. 3) Phase 2a Trial in MASH – Running with supportive scientific advice from the EMA and targeting highly underserved metabolic liver disease. With growing clinical momentum and a unique sulfur-based platform, TTI is positioned at the forefront of mitochondrial medicine. Latest News Breakdown: https://x.com/StckMasterFlash/status/1937894383744934106 Posted on Behalf of Thiogenesis Therapeutics Corp.
0 · Reply
wavess
wavess Jun. 26 at 4:30 PM
$TTIPF Yesterday, Thiogenesis Therapeutics announced it has secured a major regulatory milestone in Europe—receiving supportive scientific advice from the EMA to initiate a Phase 2a trial of TTI-0102 in children with MASH, a serious and underserved metabolic liver disease. This marks the third active Phase 2 program for TTI-0102, adding to ongoing trials for MELAS in Europe and Leigh syndrome in the U.S., and further solidifies the company’s IP and regulatory footing with new EU patent protection through 2038. With multiple rare disease indications now advancing in parallel, TTI is rapidly positioning itself as a clinical-stage leader in pediatric mitochondrial and metabolic therapeutics. Check out the full story here: https://x.com/StckMasterFlash/status/1937894383744934106 Posted on Behalf of Thiogenesis Therapeutics Corp.
0 · Reply
wavess
wavess Jun. 25 at 3:11 PM
$TTIPF Today, Thiogenesis Therapeutics announced that the European Medicines Agency (EMA) has provided supportive scientific advice for Thiogenesis’ Investigational Medicinal Product Dossier (IMPD), enabling a Phase 2a clinical trial of TTI‑0102 in pediatric patients with metabolic dysfunction-associated steatohepatitis (MASH): [NEWS RELEASE] This development advances TTI-0102 as a promising therapeutic candidate across multiple pediatric mitochondrial and metabolic diseases and strengthens TTI's IP and regulatory position in Europe amid its ongoing Phase 2 trials in Europe for MELAS as well as its IND-cleared Phase 2a trial for Leigh syndrome (LSS) in the U.S. More info on TTI's other trials: https://x.com/StckMasterFlash/status/1937578501932192183
0 · Reply
newsfile_corp
newsfile_corp Jun. 25 at 1:01 PM
https://nfne.ws/256736 $TTIPF $TTI.TSXV #InvestmentBanking #Patent #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Investing
0 · Reply
wavess
wavess Jun. 24 at 6:24 PM
$TTIPF June has marked a busy month for Thiogenesis Therapeutics, advancing its position as a leader in mitochondrial medicine with major clinical momentum this month across both sides of the Atlantic. TTI initiated a Phase 2a trial for Leigh Syndrome Spectrum in collaboration with the Children’s Hospital of Philadelphia (CHOP)—one of the world’s foremost centers in pediatric mitochondrial disorders: https://x.com/StckMasterFlash/status/1932861013423984766 Simultaneously, TTI is actively dosing patients in its Phase 2 trial for MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes) at clinical sites across Europe: https://x.com/StckMasterFlash/status/1922740812284055630
0 · Reply